Overview

Efficacy of FOLFOX+Bevacizumab in Combination With Irinotecan in the Treatment of Metastatic Colorectal Cancer

Status:
Completed
Trial end date:
2018-08-15
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the efficacy of Irinotecan in combination with FOLFOX+Bevacizumab versus FOLFOX+Bevacizumab alone in the first-line treatment of patients with metastatic colorectal cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Martin-Luther-Universität Halle-Wittenberg
Collaborator:
Roche Pharma AG
Treatments:
Bevacizumab
Camptothecin
Fluorouracil
Irinotecan
Oxaliplatin